<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558190</url>
  </required_header>
  <id_info>
    <org_study_id>mtROS-IR</org_study_id>
    <nct_id>NCT04558190</nct_id>
  </id_info>
  <brief_title>Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle</brief_title>
  <official_title>Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the link between insulin resistance and alterations&#xD;
      in skeletal muscle mitochondrial redox homeostasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole body Insulin sensitivity</measure>
    <time_frame>5 hours after lipid infusion</time_frame>
    <description>Whole body insulin sensitivity is determined by hyperinsulinemic isoglycemic clamp method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle insulin sensitivity</measure>
    <time_frame>5 hours after lipid infusion</time_frame>
    <description>Insulin-dependent skeletal muscle glucose uptake is determined by hyperinsulinemic isoglycemic clamp method integrated with measurements of femoral artery blood flow and arteriovenous difference of glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial respiration</measure>
    <time_frame>Baseline</time_frame>
    <description>Mitochondrial O2 flux is determined in skeletal muscle biopsies by high-resolution fluorespirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial reactive oxygen species</measure>
    <time_frame>Baseline</time_frame>
    <description>Mitochondrial H2O2 emission rate is determined in skeletal muscle biopsies by high-resolution fluorespirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial oxidative stress</measure>
    <time_frame>Before (baseline) as well as 3 and 5 hours after lipid infusion</time_frame>
    <description>Peroxiredoxin3 dimer/monomer ratio is determined in skeletal muscle biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle redox status</measure>
    <time_frame>Before (baseline) as well as 3 and 5 hours after lipid infusion</time_frame>
    <description>GSH/GSSG ratio is determined in skeletal muscle biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin signalling</measure>
    <time_frame>Before (baseline) as well as 3 and 5 hours after lipid infusion</time_frame>
    <description>Phosphorylation status of proteins modulating insulin action is determined in skeletal muscle biopsies</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiorespiratory fitness</measure>
    <time_frame>Baseline</time_frame>
    <description>Pulmonary maximal oxygen uptake (VO2max) is determined during an incremental exercise test to exhaustion</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Fat free mass and fat mass are determined by dual-energy X-ray absorptiometry (DXA)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Lipid infusion + MitoQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by MitoQ administration and intravenous lipid infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipid infusion + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by placebo administration and intravenous lipid infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects undergo a hyperinsulinemic isoglycemic clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipid infusion + beta2-agonist</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects undergo a hyperinsulinemic isoglycemic clamp with intravenous infusion of lipid and salbutamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid, 20% Intravenous Emulsion</intervention_name>
    <description>Lipid infusion</description>
    <arm_group_label>Lipid infusion + MitoQ</arm_group_label>
    <arm_group_label>Lipid infusion + beta2-agonist</arm_group_label>
    <arm_group_label>Lipid infusion + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MitoQ</intervention_name>
    <description>Oral administration of MitoQ capsules</description>
    <arm_group_label>Lipid infusion + MitoQ</arm_group_label>
    <other_name>Mitoquinone mesylate</other_name>
    <other_name>Mitoquinone</other_name>
    <other_name>MitoQ10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Beta2-agonist infusion</description>
    <arm_group_label>Lipid infusion + beta2-agonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥25 and &lt;40 kg/m2&#xD;
&#xD;
          -  Fasting plasma glucose ≥ 5.6 mmol/L or HbA1c ≥ 5.7%&#xD;
&#xD;
          -  HOMA2-IR &gt; 1.4&#xD;
&#xD;
          -  VO2max &lt;45 ml/kg/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with &gt;2 antidiabetic medications&#xD;
&#xD;
          -  Insulin usage&#xD;
&#xD;
          -  Chronic disease deemed by the study responsible medical doctor to interfere with any&#xD;
             part of the study&#xD;
&#xD;
          -  Chronic use of prescription medicine deemed by the study responsible medical doctor to&#xD;
             interfere with any part of the study&#xD;
&#xD;
          -  Smoking&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>August Krogh Building</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Hostrup, PhD</last_name>
      <phone>+4524474785</phone>
      <email>mhostrup@nexs.ku.dk</email>
    </contact>
    <investigator>
      <last_name>Matteo Fiorenza, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hostrup, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

